Jeremy Bender, Day One Biopharmaceuticals CEO
June 7, 2023 07:34 AM EDT
Financing
R&D

Day One goes to the mar­ket for $150M as biotech kicks off NDA re­quest for pe­di­atric brain can­cer drug

Kyle LaHucik

Senior Reporter

Day One Bio­phar­ma­ceu­ti­cals will of­fer up more than 11.5 mil­lion shares to nab $150 mil­lion in gross pro­ceeds af­ter the biotech …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Boehringer’s up­dat­ed re­sults in HER2-mu­tat­ed lung can­cer im­press

No­vavax re­sponds to FDA’s tri­al ask, with Covid vac­cine strain up­dates un­der scruti­ny

Schol­ar Rock names new CEO, adds biotech vet­er­ans in C-suite re­build

Mer­ck KGaA to buy rare can­cer biotech Spring­Works for $3.9B

GSK’s check­point block­er Jem­per­li cures bio­mark­er-dri­ven rec­tal can­cer

sponsored

Rev­o­lu­tion­iz­ing obe­si­ty treat­ment: Could mi­to­chon­dria hold the key to un­lock­ing fat-spe­cif­ic weight loss?

A service from the Financial Times